<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03985410</url>
  </required_header>
  <id_info>
    <org_study_id>CS2514-2018-0003</org_study_id>
    <nct_id>NCT03985410</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers</brief_title>
  <official_title>A Randomized, Three Period Crossover Thorough QT (TQT) Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entasis Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entasis Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the effects of supratherapeutic ETX2514 plasma
      concentrations on the heart rate-corrected QT interval (QTc).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Actual">July 24, 2019</completion_date>
  <primary_completion_date type="Actual">July 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The administration of ETX2514 and ETX2514 placebo will be double-blinded. Placebo and moxifloxacin (Treatment Period C) will be administered open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected change from Baseline in Fridericia-corrected QTc (QTcF) (ΔΔQTcF)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart rate (HR) (ΔHR)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in QTcF (ΔQTcF)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the PR interval (ΔPR)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the QRS interval (ΔQRS)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change from Baseline in HR (ΔΔHR)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change from Baseline in PR (ΔΔPR)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change from Baseline in QRS (ΔΔQRS)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with categorical outliers for QTcF, HR, PR, and QRS</measure>
    <time_frame>up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent changes of T-wave morphology and U-wave presence</measure>
    <time_frame>up to Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Acinetobacter Baumannii-calcoaceticus Complex Infections</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour intravenous (IV) infusion of 4 grams (g) of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 milligrams (mg) open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETX2514</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, male or female, 18-55 years of age, inclusive, at Screening

          -  Continuous non-smoker who has not used nicotine-containing products for at least 3
             months prior to the first dose

          -  Must weigh at least 60 kilograms (kg) for males or 52 kg for females and have a body
             mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/meters squared (m^2) at Screening.

          -  Medically healthy with no clinically significant medical history, physical
             examination, laboratory profiles, vital signs, or electrocardiograms (ECGs), as deemed
             by the Principal Investigator (PI)

          -  Women of childbearing potential (i.e., not post-menopausal or surgically sterilized)
             must have a negative serum pregnancy test before randomization. Participating
             heterosexual women of childbearing potential must be willing to consistently use 2
             highly effective methods of contraception (i.e., condom with spermicide, combined oral
             contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized
             partner) from Screening until at least 30 days after administration of the last dose
             of study drug; and

          -  Non-childbearing women must have had a hysterectomy, surgical sterilization, or be
             postmenopausal at least 12 months prior to Screening.

          -  Male participants must be willing to use condoms with spermicide during sexual
             intercourse from Screening until at least 90 days after administration of the last
             dose of study drug.

          -  Male participants with a vasectomy must have had the vasectomy at least 90 days prior
             to randomization.

          -  Male participants must agree not to donate sperm from the Screening period through 90
             days after the last dose.

          -  Understands the study procedures in the informed consent form and is willing and able
             to comply with the protocol

          -  Able to swallow tablets

          -  Supine blood pressure between 90/40 millimeters of mercury (mmHg) and 140/90 mmHg
             (inclusive) at Screening

          -  No clinically significant history or presence of ECG findings as judged by the PI at
             Screening and check-in, including each criterion as listed below:

               1. Normal sinus rhythm (heart rate between 45 beats per minute [bpm] and 100 bpm
                  inclusive);

               2. Fridericia-corrected QTc (QTcF) interval &lt; 450 milliseconds (msec);

               3. QRS interval ≤ 110 msec; and confirmed by manual over read if &gt; 110 msec;

               4. PR interval ≤ 220 msec;

               5. No electrographically significant abnormalities that might interfere with ECG
                  analysis including evidence of a previous myocardial infarction (MI), significant
                  left ventricular hypertrophy (LVH), flat T-waves (particularly in the inferior
                  leads) or more than minor non-specific ST-T wave changes

          -  Has serum potassium, calcium, and magnesium levels within the normal range at
             Screening

        Exclusion Criteria:

          -  Participant is mentally or legally incapacitated or has significant emotional problems
             at the time of the Screening visit or expected during the conduct of the study.

          -  History or presence of clinically significant medical or psychiatric condition or
             disease in the opinion of the PI

          -  History of any illness that, in the opinion of the PI, might confound the results of
             the study or poses an additional risk to the participant by their participation in the
             study

          -  History or presence of alcoholism or drug abuse within the past 2 years prior to the
             first dose of study drug

          -  History or presence of hypersensitivity or idiosyncratic reaction to the study drugs,
             related compounds, or inactive ingredients

          -  History of significant multiple and/or severe allergies (e.g., latex allergy, band
             aids, adhesive dressing, or medical tape), or has had an anaphylactic reaction or
             significant intolerability to prescription or non-prescription drugs

          -  Female participants who are pregnant or lactating

          -  Positive urine drug or alcohol results at Screening or check-in

          -  Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HbsAg), or hepatitis C virus (HCV)

          -  Unable to refrain from or anticipates the use of:

               1. Any drug, including prescription and non-prescription medications (including
                  antacids), herbal remedies, or vitamin supplements (especially those containing
                  magnesium, aluminum, iron, or zinc) beginning 14 days prior to the first dose of
                  study drug and throughout the study. Co-administration of ETX2514 and probenecid
                  is prohibited.

               2. Any drugs known to be significant inhibitors or inducers of cytochrome P450 (CYP)
                  enzymes and/or permeability glycoprotein (P-gp), including St. John's Wort, for
                  28 days prior to the first dose of study drug and throughout the study.

          -  Has been on a diet incompatible with the on-study diet (including an extreme diet
             which resulted in a significant weight change for whatever reason), in the opinion of
             the PI, within the 28 days prior to the first dose of study drug, and throughout the
             study

          -  Donation of blood or significant blood loss more than 500 milliliters (mL) within 56
             days prior to the first dose of study drug

          -  Plasma donation within 7 days prior to the first dose of study drug

          -  Has had surgery or any medical condition which may affect the absorption,
             distribution, metabolism, or elimination of the study drug within 6 months prior to
             the first dose, in the opinion of the PI

          -  Participation in another clinical trial within 28 days prior to the first dose of
             study drug. The 28-day window will be derived from the date of the last blood
             collection or dosing, whichever is later, in the previous study to Day 1 of the
             current study.

          -  Participation in a previous clinical trial where participant received ETX2514

          -  History or presence of:

               1. hypokalemia, in the opinion of the PI;

               2. risk factors for Torsades de Pointes (e.g., heart failure, cardiomyopathy, or
                  family history of Long QT Syndrome);

               3. sick sinus syndrome, second- or third-degree atrioventricular block, pulmonary
                  congestion, cardiac arrhythmia, prolonged QT interval, or conduction
                  abnormalities;

               4. repeated or frequent vasovagal episodes:

                    -  hypertension, angina, bradycardia, or severe peripheral arterial circulatory
                       disorders;

                    -  history or evidence of any of the following: MI, cardiac valvulopathy,
                       cardiac surgery revascularization (coronary artery bypass grafting or
                       percutaneous transluminal coronary angioplasty), unstable angina,
                       cerebrovascular accident or stroke or transient ischemic attack (TIA),
                       pacemaker; atrial fibrillation, flutter, or non-sustained or sustained
                       ventricular tachycardia (VT); pulmonary arterial hypertension; unexplained
                       syncope or syncope within the last 3 years regardless of etiology; and/or
                       history of hypokalemia

          -  Participant has a history within the last 6 months of frequent strenuous exercise,
             and/or is unwilling to refrain from strenuous exercise from 7 days prior to baseline
             Day -1 through the last Follow-Up Visit.

          -  Participants who refused to abstain from caffeine-containing foods or caffeinated
             beverages (e.g., coffee, tea, cola, energy drinks) for 7 days prior to Day -1 through
             the last Follow-up Visit

          -  Participants who refused to abstain from alcohol from 7 days prior to Day -1 through
             the last Follow-Up Visit

          -  Participants who refused to abstain from grapefruit-containing foods or beverages or
             Seville orange-containing foods or beverages from 2 weeks prior to Day -1 through the
             last Follow-Up Visit

          -  Participant has consumed cruciferous vegetables (e.g., kale, broccoli, watercress,
             collard greens, kohlrabi, Brussels sprouts, and mustard greens) or charbroiled meats
             within 7 days prior to check-in through the last Follow-up Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmaron Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acinetobacter baumannii-calcoaceticus</keyword>
  <keyword>complex infections</keyword>
  <keyword>ETX2514</keyword>
  <keyword>cardiac repolarization</keyword>
  <keyword>heart rate-corrected QT interval (QTc)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

